{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:28:27Z","timestamp":1791404907794,"version":"4.3.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40801-017-0110-0","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T06:46:00Z","timestamp":1496990760000},"page":"151-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System"],"prefix":"10.1007","volume":"4","author":[{"given":"Didier","family":"Nzolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Anto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hailemariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Bakajika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Muteba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Makenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Mesia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestin","family":"Nsibu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Mampunza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Tona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"issue":"7","key":"110_CR1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1469-0691.2011.03586.x","volume":"17","author":"A Hoerauf","year":"2011","unstructured":"Hoerauf A, Pfarr K, Mand S, Debrah AY, Specht S. Filariasis in Africa\u2013treatment challenges and prospects. Clin Microbiol Infect. 2011;17(7):977\u201385.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"110_CR2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.pt.2003.09.004","volume":"19","author":"DH Molyneux","year":"2003","unstructured":"Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol. 2003;19(11):516\u201322.","journal-title":"Trends Parasitol."},{"key":"110_CR3","unstructured":"African Programme for Onchocerciasis Control: Meeting of National Onchocerciasis Task Forces, September 2013. Wkly Epidemiol Rec. 2013;88(50):533\u201344. http:\/\/www.who.int\/wer\/2013\/wer8850.pdf?ua=1 ."},{"key":"110_CR4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1756-3305-4-178","volume":"4","author":"LA Kelly-Hope","year":"2011","unstructured":"Kelly-Hope LA, Thomas BC, Bockarie MJ, Molyneux DH. Lymphatic filariasis in the Democratic Republic of Congo; micro-stratification overlap mapping (MOM) as a prerequisite for control and surveillance. Parasit Vectors. 2011;4:178.","journal-title":"Parasit Vectors"},{"issue":"1","key":"110_CR5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/tmi.12397","volume":"20","author":"JC Makenga Bof","year":"2015","unstructured":"Makenga Bof JC, Maketa V, Bakajika DK, Ntumba F, Mpunga D, Murdoch ME, Hopkins A, Noma MM, Zour\u00e9 H, Tekle AH, Katabarwa MN, Lutumba P. Onchocerciasis control in the Democratic Republic of Congo (DRC): challenges in a post-war environment. Trop Med Int Health. 2015;20(1):48\u201362.","journal-title":"Trop Med Int Health."},{"issue":"12","key":"110_CR6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0169-4758(98)01342-8","volume":"14","author":"SE Meredith","year":"1998","unstructured":"Meredith SE, Dull HB. Onchocerciasis: the First Decade of Mectizan\u2122 Treatment. Parasitol Today. 1998;14(12):472\u20134.","journal-title":"Parasitol Today"},{"issue":"11","key":"110_CR7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.pt.2005.08.014","volume":"21","author":"TG Geary","year":"2005","unstructured":"Geary TG. Ivermectin 20\u00a0years on: maturation of a wonder drug. Trends Parasitol. 2005;21(11):530\u20132.","journal-title":"Trends Parasitol."},{"issue":"Suppl 1","key":"110_CR8","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1475-2883-2-S1-S4","volume":"2","author":"M Boussinesq","year":"2003","unstructured":"Boussinesq M, Gardon J, Gardon-wendel N, Chippaux JP. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J. 2003;2(Suppl 1):S4. doi: 10.1186\/1475-2883-2-S1-S4 .","journal-title":"Filaria J"},{"issue":"6","key":"110_CR9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pt.2007.04.007","volume":"23","author":"C Mackenzie","year":"2007","unstructured":"Mackenzie C, Geary T, Prichard R, Boussinesq M. Where next with Loa loa encephalopathy? Data are badly needed. Trends Parasitol. 2007;23(6):237\u20138.","journal-title":"Trends Parasitol"},{"issue":"286","key":"110_CR10","doi-asserted-by":"crossref","first-page":"286re4","DOI":"10.1126\/scitranslmed.aaa3480","volume":"7","author":"MV D\u2019ambrosio","year":"2015","unstructured":"D\u2019ambrosio MV, Bakalar M, Bennuru S, Reber C, Skandarajah A, Nilsson L, Switz N, Kamgno J, Pion S, Boussinesq M, Nutman TB, Fletcher DA. Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Sci Transl Med. 2015;7(286):286re4.","journal-title":"Sci Transl Med."},{"issue":"Suppl 1","key":"110_CR11","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1475-2883-2-S1-S7","volume":"2","author":"NA Twum-danso","year":"2003","unstructured":"Twum-danso NA. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J. 2003;2(Suppl 1):S7.","journal-title":"Filaria J"},{"issue":"Suppl 1","key":"110_CR12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1475-2883-2-S1-S3","volume":"2","author":"NA Twum-danso","year":"2003","unstructured":"Twum-danso NA. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J. 2003;2(Suppl 1):S3.","journal-title":"Filaria J"},{"issue":"4","key":"110_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4269\/ajtmh.1998.58.461","volume":"58","author":"M Boussinesq","year":"1998","unstructured":"Boussinesq M, Gardon J, Gardon-wendel N, Kamgno J, Ngoumou P, Chippaux JP. Three probable cases of loa loa encephalopathy following ivermectin treatment for onchocerciasis. Am J Trop Med Hyg. 1998;58(4):461\u20139.","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"110_CR14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4269\/ajtmh.2008.78.546","volume":"78","author":"J Kamgno","year":"2008","unstructured":"Kamgno J, Boussinesq M, Labrousse F, Nkegoum B, Thylefors BI, Mackenzie CD. Case Report: encephalopathy after Ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. Am J Trop Med Hyg. 2008;78(4):546\u201351.","journal-title":"Am J Trop Med Hyg"},{"key":"110_CR15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1756-3305-7-307","volume":"7","author":"LA Kelly-hope","year":"2014","unstructured":"Kelly-hope LA, Cano J, Stanton MC, Bockarie MJ, Molyneux DH. Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: the application of micro-stratification mapping. Parasit Vectors. 2014;7:307.","journal-title":"Parasit Vectors"},{"issue":"Suppl 1","key":"110_CR16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1475-2883-2-S1-S1","volume":"2","author":"BO Duke","year":"2003","unstructured":"Duke BO. Overview: report of a Scientific Working Group on serious adverse events following Mectizan \u00ae treatment of onchocerciasis in Loa loa endemic areas. Filaria J. 2003;2(Suppl 1):S1.","journal-title":"Filaria J"},{"issue":"9070","key":"110_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","volume":"350","author":"J Gardon","year":"2003","unstructured":"Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350(9070):18\u201322. doi: 10.1016\/S0140-6736(96)11094-1 .","journal-title":"Lancet"},{"issue":"9","key":"110_CR18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1046\/j.1365-3156.2003.01091.x","volume":"8","author":"NA Twum-Danso","year":"2003","unstructured":"Twum-Danso NA, Meredith SE. Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis. Trop Med Health. 2003;8(9):820\u201331.","journal-title":"Trop Med Health"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-017-0110-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-017-0110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-017-0110-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T16:48:56Z","timestamp":1569430136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-017-0110-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1007\/s40801-017-0110-0","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]}}}